Background: A randomized trial conducted by the Gynecologic Oncology Group (GOG,
study# 111) in the United States showed a better outcome for patients with advanced …

Background Previous studies on prognostic factors in stage I invasive epithelial ovarian
carcinoma have been too small for robust conclusions to be reached. We undertook a …

Paroxetine, a selective serotonin reuptake inhibitor, is a potent inhibitor of cytochrome P450
2D6 (CYP2D6) activity, but the mechanism of inhibition is not established. To determine …

Background During an international workshop held in September 1998, a group of
specialists in the field of ovarian cancer reached consensus on a number of issues with …

The objective of the study was to evaluate the prognostic effect of p53, Her-2, and EGFR in
borderline and epithelial ovarian cancer. Tumor tissue from 85 patients with borderline and …

Two independent and consecutive randomized clinical trials, conducted by the American
Gynecological Oncology Group and by an European–Canadian Intergroup, have shown …

Results obtained during the first 5 years of a randomized study of postoperative radiotherapy
(50 Gy) are presented. Criteria for randomization were fulfilled in 494 of 861 patients with …

Three hundred sixty-one patients with FIGO stage III and IV ovarian cancer were treated with
cis-platinum combination chemotherapy in a Danish multicenter trial. Primary surgery was …

Two hundred-two patients with FIGO stages III and IV epithelial ovarian cancer were
randomized to 6 or 12 cycles of cyclophosphamide, Adriamycin, and cisplatin (CAP) …

Oriented-sample solid-state NMR represents one of few experimental methods capable of
characterising the membrane-bound conformation of proteins in the cell membrane. Since …